In the BioHarmony Drug Report Database

"Preview" Icon

Crizotinib

Xalkori (crizotinib) is a small molecule pharmaceutical. Crizotinib was first approved as Xalkori on 2011-08-26. It is used to treat non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat non-small-cell lung carcinoma. The pharmaceutical is active against ALK tyrosine kinase receptor. In addition, it is known to target hepatocyte growth factor receptor. Xalkori’s patents are valid until 2029-11-06 (FDA).

 

Trade Name

 

Xalkori
 

Common Name

 

crizotinib
 

ChEMBL ID

 

CHEMBL601719
 

Indication

 

non-small-cell lung carcinoma
 

Drug Class

 

Tyrosine kinase inhibitors

Image (chem structure or protein)

Crizotinib structure rendering